{
  "nctId": "NCT02183792",
  "briefTitle": "Aquaresis Utility for Hyponatremic Acute Heart Failure Study",
  "officialTitle": "Aquaresis Utility for Hyponatremic Acute Heart Failure Study",
  "protocolDocument": {
    "nctId": "NCT02183792",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2017-08-09",
    "uploadDate": "2019-05-24T11:29",
    "size": 347290,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02183792/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 33,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2014-12",
    "completionDate": "2018-03",
    "primaryCompletionDate": "2018-02",
    "firstSubmitDate": "2014-06-25",
    "firstPostDate": "2014-07-08"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Acute HF with signs or symptoms of volume overload \\[i.e. elevated jugular venous pulsation (JVP), rales, edema\\]\n* Serum sodium \\< 135 mEq/L at time of or within first 48 hours of hospitalization\n* Randomized within 48 hours of presentation to hospital\n* â‰¥ 18 years of age\n* Informed consent\n\nExclusion Criteria:\n\n* Severe symptomatic hyponatremia requiring acute treatment\n* Severe renal impairment upon admission (creatinine clearance \\< 20 mL/min)\n* Renal replacement therapy dependent, or requiring upon admission\n* Acute coronary syndrome on admission\n* Requires or has a mechanical circulatory support device\n* Evidence of cardiogenic shock requiring intravenous vasopressors\n* Pregnancy\n* Patient requiring concomitant use of strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin)",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Median Urine Output at 24 Hours Post Randomization",
        "timeFrame": "24 hours post randomization"
      }
    ],
    "secondary": [
      {
        "measure": "Median Change in Serum Creatinine at 24 Hours Post Randomization",
        "description": "Comparison between baseline and 24 hours post randomization concentrations.",
        "timeFrame": "24 hours post randomization"
      }
    ],
    "other": [
      {
        "measure": "Total Urine Output",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Glomerular Filtration Rate (Estimated)",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "In-hospital Mortality",
        "timeFrame": "Participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Mean Hourly Urine Output at 24 Hours",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Serum Sodium Change",
        "description": "Difference assessed at baseline, 8, 24, 48, 72 and 96 hours.",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Weight Change",
        "description": "Difference assessed at baseline, 8, 24, 48, 72 and 96 hours.",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Cumulative Furosemide Dose",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Cumulative Metolazone Use",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Change in Self-rated Dyspnea",
        "timeFrame": "At baseline, 24 and 96 hours post randomization"
      },
      {
        "measure": "Acute Worsening of Kidney Function (Defined as an Increase in Serum Creatinine 0.3 mg/dL or 25% Above Baseline)",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Incidence of Electrolyte Abnormalities",
        "description": "Hypo- and hyperkalemia defined as outside the range of 3.5 to 5.0 mEq/L Hypo- and hypermagnesemia defined as outside the range of 1.5-2.4 mEq/L",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Symptomatic Hypotension",
        "timeFrame": "Up to 96 hours post randomization and participants will be followed for the duration of hospital stay, an expected average of 5 days"
      },
      {
        "measure": "Change in Plasma Renin Activity",
        "timeFrame": "At baseline, 24 and 96 hours post randomization"
      },
      {
        "measure": "Change in Copeptin",
        "timeFrame": "At baseline, 24 and 96 hours post randomization"
      },
      {
        "measure": "Change in N-terminal Pro-B-type Natriuretic Peptide",
        "timeFrame": "At baseline, 24 and 96 hours post randomization"
      },
      {
        "measure": "Change in Cystatin C",
        "timeFrame": "At baseline, 24 and 96 hours post randomization"
      },
      {
        "measure": "Change in Urinary Neutrophil Gelatinase-associated Lipocalin (NGAL)",
        "timeFrame": "At baseline, 24, 48, 72 and 96 hours post randomization"
      },
      {
        "measure": "Hospital Length of Stay",
        "timeFrame": "Participants will be followed for the duration of hospital stay, an expected average of 5 days"
      }
    ]
  },
  "realComplexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 5,
      "exclusionCount": 8,
      "totalCount": 13
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 18,
      "totalCount": 20
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 87,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-21T22:32:40.484Z",
  "dataSource": "ClinicalTrials.gov API v2"
}